Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

Bossie, Cynthia A; Sliwa, Jennifer K; Yi-Wen Ma; Dong-Jing Fu; Alphs, Larry
January 2011
BMC Psychiatry;2011, Vol. 11 Issue 1, p79
Academic Journal
Background: Paliperidone palmitate is a long-acting injectable atypical antipsychotic for the acute and maintenance treatment of adults with schizophrenia. The recommended initiation dosing regimen is 234 mg on Day 1 and 156 mg on Day 8 via intramuscular (deltoid) injection; followed by 39 to 234 mg once-monthly thereafter (deltoid or gluteal). These post-hoc analyses addressed two commonly encountered clinical issues regarding the initiation dosing: the time to onset of efficacy and the associated tolerability. Methods: In a 13-week double-blind trial, 652 subjects with schizophrenia were randomized to paliperidone palmitate 39, 156, or 234 mg (corresponding to 25, 100, or 150 mg equivalents of paliperidone, respectively) or placebo (NCT#00590577). Subjects randomized to paliperidone palmitate received 234 mg on Day 1, followed by their randomized fixed dose on Day 8, and monthly thereafter, with no oral antipsychotic supplementation. The onset of efficacy was defined as the first timepoint where the paliperidone palmitate group showed significant improvement in the Positive and Negative Syndrome Scale (PANSS) score compared to placebo (Analysis of Covariance [ANCOVA] models and Last Observation Carried Forward [LOCF] methodology without adjusting for multiplicity) using data from the Days 4, 8, 22, and 36 assessments. Adverse event (AE) rates and relative risks (RR) with 95% confidence intervals (CI) versus placebo were determined. Results: Paliperidone palmitate 234 mg on Day 1 was associated with greater improvement than placebo on Least Squares (LS) mean PANSS total score at Day 8 (p = 0.037). After the Day 8 injection of 156 mg, there was continued PANSS improvement at Day 22 (p ⩽ 0.007 vs. placebo) and Day 36 (p < 0.001). Taken together with results in the 39 mg and 234 mg Day 8 arms, these findings suggest a trend towards a dose-dependent response. During Days 1 to 7, AEs reported in ⩾2% of paliperidone palmitate subjects (234 mg) and a greater proportion of paliperidone palmitate than placebo subjects were: agitation (3.2% vs. 1.3%; RR 2.52 [95% CI 0.583, 10.904]), headache (4.0% vs. 3.8%; RR 1.06 [95% CI 0.433, 2.619]), and injection site pain (6.7% vs. 3.8%; RR 1.79 [95% CI 0.764, 4.208]). Days 8 to 36 AEs meeting the same criteria in the 156 mg Day 8 arm were: anxiety (3.1% vs. 2.5%; RR 1.24 [95% CI 0.340, 4.542]), psychotic disorder (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]), dizziness (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]), and injection site pain (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]). Corresponding Days 8 to 36 AEs in the 39 mg Day 8 group were: agitation (4.5% vs. 4.4%; RR 1.03 [95% CI 0.371, 2.874]), anxiety (3.9% vs. 2.5%; RR 1.55 [95% CI 0.446, 5.381]), and psychotic disorder (2.6% vs. 1.3%; RR 2.07 [95% CI 0.384, 11.110]) while in the 234 mg Day 8 group it was anxiety (3.1% vs. 2.5%, RR 1.25 [95% CI 0.342, 4.570]) Conclusions: Significantly greater symptom improvement was observed by Day 8 with paliperidone palmitate (234 mg on Day 1) compared to placebo; this effect was maintained after the 156 mg Day 8 injection, with a trend towards a dose-dependent response. No unexpected tolerability findings were noted in the first week or month after the initiation dosing. Trial registration: ClinicalTrials.gov: NCT#00590577


Related Articles

  • Peer Review of "Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol". Peuskens, J. // British Journal of Psychiatry;Jun95, Vol. 166, p727 

    The article presents a peer review of the study "Risperidone in the Treatment of Patients with Chronic Schizophrenia: A Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol," by J. Peuskens. The assessments presents two reviewers' comments on both the original and...

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • Neuronal Dysfunction of the Frontal Lobe in Schizophrenia. Chi-Un Pae; Bo-Young Choe; Ra-Hyeong Joo; Hyun-Kook Lim; Tae-Suk Kim; Seung-Schik Yoo; Byung-Gil Choi; Jung-Jin Kim; Soo-Jung Lee; Chul Lee; In-Ho Paik; Chang Uk Lee // Neuropsychobiology;2004, Vol. 50 Issue 3, p211 

    Localized in vivo proton magnetic resonance spectroscopy (MRS) was performed to evaluate metabolic alterations in the right and left frontal lobe before and after antipsychotic treatment of schizophrenic patients (n = 24) and a group of healthy normal subjects (n = 20). Proton metabolic ratios...

  • BioLineRx to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p497 

    The article reports on the announcement of BioLineRx Ltd. on the release of data from the completed phase IIb trial of GABA-enhanced antipsychotic BL-1020 to be presented at the3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany. The trial has demonstrated the...

  • Computerised tomography in newly diagnosed schizophrenia and schizophreniform disorder. A controlled blind study. Rubin, Pia; Karle, Agnete; MøLler-Madsen, Susanne; Hertel, Charlotte; Povlsen, Uffe Juul; Noring, Ulla; Hemmingsen, Ralf; Rubin, P; Karle, A; Møller-Madsen, S; Hertel, C; Povlsen, U J; Noring, U; Hemmingsen, R // British Journal of Psychiatry;Nov93, Vol. 163, p604 

    Patients with newly diagnosed schizophrenia (n = 27) or schizophreniform disorder (n = 22) and 24 healthy volunteers were investigated by CT scan, the investigators being blind to subject status. The patients had never received medication or had been treated only briefly with neuroleptics. The...

  • Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Tonin, Fernanda S.; Wiens, Astrid; Fernandez-Llimos, Fernando; Pontarolo, Roberto // Core Evidence;2016, Vol. 11, p49 

    Introduction: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel...

  • The Pulse on Study Conduct. Weeks-Rowe, Elizabeth // CenterWatch Weekly;1/20/2014, Vol. 18 Issue 3, p6 

    The article reports on developing successful relationships with investigational sites in clinical research. It is said that collective research for advanced therapeutics includes a dynamic conviction to push forward, despite challenges. Despite the growing number of participants, clinical...

  • Evolution and Translation of Research Findings: From Bench to Where? Ioannidis, John P. A. // PLoS Clinical Trials;Nov2006, Vol. 3 Issue 11, p0001 

    The credibility and replication of research findings evolve over time, as data accumulate. However, translation of postulated research promises to real-life biomedical applications is uncommon. In some fields of research, we may observe diminishing effects for the strength of research findings...

  • How does long-term odor deprivation affect the olfactory capacity of adult mice? Angely, Cathy J.; Coppola, David M. // Behavioral & Brain Functions;2010, Vol. 6, p26 

    Background: Unilateral naris occlusion (UNO) has been the most common method of effecting stimulus deprivation in studies of olfactory plasticity. However, despite the large corpus on the effects of this manipulation, dating back to the 19th century, little is known about its behavioral sequela....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics